## 1 2

3

# Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention

4 Bryan T. Mayer [1], Allan C. deCamp [1], Yunda Huang [1,2,3], Joshua T. Schiffer [1,4,5], Raphael Gottardo 5 [1], Peter B. Gilbert [1,6], Daniel B. Reeves\*[1]

[1] Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle WA, USA

[2] Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle WA, USA

6 7 8 9 [3] Department of Global Health, University of Washington, Seattle, WA, USA.

10 [4] Department of Medicine, University of Washington, Seattle, WA, USA.

11 [5] Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle WA, USA

12 [6] Department of Biostatistics, University of Washington, Seattle, WA, USA.

13 \*Corresponding author dreeves@fredhutch.org

14 15

16 Abstract. Broadly neutralizing antibodies are promising agents to prevent HIV infection and achieve HIV 17 remission without antiretroviral therapy (ART). As learned from effective ART, HIV viral diversity 18 necessitates combination antibody cocktails. Here, we demonstrate how to optimally choose the ratio 19 within combinations based on the constraint of a total dose size. Optimization in terms of prevention 20 efficacy outcome requires a model that synthesizes 1) antibody pharmacokinetics (PK), 2) a mapping 21 between concentration and neutralization against a genetically diverse pathogen (e.g., distributions of 22 viral IC50 or IC80), 3) a protection correlate to translate in vitro potency to clinical protection, and 4) an 23 in vivo interaction model for how drugs work together. We find that there is not a general solution, and 24 the optimal dose ratio likely will be different if antibodies cooperate versus if both products must be 25 simultaneously present. Optimization requires trade-offs between potency and longevity; using an in silico 26 case-study, we show a cocktail can outperform a bi-specific antibody (a single drug with 2 merged 27 antibodies) with superior potency but worse longevity. In another practical case study, we perform a triple 28 antibody optimization of VRC07, 3BNC117, and 10-1074 bNAb variants using empirical PK and a pre-29 clinical correlate of protection derived from animal challenge studies. Here, a 2:1:1 dose emphasizing 30 VRC07 would optimally balance protection while achieving practical dosing and given conservative 31 judgements about prior data. Our approach can be immediately applied to optimize the next generation 32 of combination antibody prevention and cure studies.

#### Introduction 33

34

35 Broadly neutralizing antibodies (bNAbs) are powerful agents that may become crucial for next generation 36 HIV prevention<sup>1</sup>. Their utility is strengthened by their generally long half-lives compared to small molecule

37 drugs, as well as the eventual promise of inducing bNAb production by vaccination $^{2,3}$ .

38 The recent antibody mediated prevention (AMP) studies directly tested the hypothesis that the VRC01

39 bNAb could prevent HIV acquisition<sup>4,5</sup>. While the study found no significant overall prevention efficacy,

40 once HIV-1 Envelope pseudoviruses were made based on viral sequences from trial participants who

41 acquired HIV-1 infection, it emerged that viruses acquired by placebo recipients were more sensitive to

42 neutralization by VRC01 than viruses acquired by VRC01 recipients. The prevention efficacy against

- 43 sensitive viruses (sensitive was defined as IC80 < 1  $\mu$ g/ml) was estimated at 75.4% (95% confidence
- 44 interval 45.5 to 88.9%). Less sensitive variants comparatively infected placebo and control recipients<sup>5</sup>.
- 45 Indeed, the diversity of globally circulating strains<sup>6</sup> remains beyond the breadth of any current bNAb. As
- 46 with antiretroviral treatment (ART) and pre-exposure prophylaxis (PreP), combinations of products are
- 47 likely needed<sup>7–9</sup>.

48 In vitro combination bNAb potency has been studied and modeled previously<sup>10,11</sup>. Here, we extend these 49 pharmacodynamic (PD) models to incorporate in vivo concentrations over time (pharmacokinetics, PK) 50 with multiple bNAb administrations to establish a PKPD framework for clinical design focusing on how to 51 ration the dose of each bNAb. A particularly important component of our modeling is that we allow bNAb 52 concentrations to vary and distinguish *in vitro* and *in vivo* potency<sup>12</sup>. As neutralization markers that best 53 predict prevention efficacy (PE) are still under investigation, we consider flexible choices of the PKPD 54 outcomes to be optimized, and also show that many outcomes are co-optimized. We apply our framework 55 to 2 realistic in silico case studies. The first is a comparison of two antibodies against a bi-specific 56 antibody<sup>13,14</sup>, a synthesized combination of the two "parental" antibodies. We assume the bi-specific gains 57 potency through the combination, but loses longevity, clearing with the faster of the two parental 58 antibody half-lives. The second study models a three-drug combination of clinical candidate bNAbs 59 (VRC07-523-LS<sup>15</sup>, 10-1074 & 3BNC117<sup>16</sup>) and applies a protection correlate—protection predicted by 60 neutralization titer—derived from non-human primate challenge studies<sup>17</sup>.

61 Our framework is designed to answer a crucial design consideration for these future studies: what is the 62 optimal ratio of multiple antibodies to deliver in a single dose of a fixed size? We show the optimal ratio 63 can depend on any and all inputs and assumptions -- precluding a one-size-fits-all solution. Instead, we 64 provide a framework and a publicly available tool to determine the best dose plan given the specific 65 antibodies, existing information about their interaction *in vivo*, and the PKPD outcome marker of interest 66 for a proposed study. As more is known about each of these components, the model framework will rely

67 on less uncertainty and become more predictive.

## 68 **Results**



69

70 Fig 1. PKPD model schematic for optimizing combination treatment against a genetically diverse 71 pathogen. The model incorporates: pharmacokinetics (PK), pharmacodynamics (PD), and interactions 72 between antibodies. The PK describes antibody concentrations over time after administration. The PD 73 model describes the distribution of neutralization potencies for each antibody against a variety of viral 74 strains (quantified here by IC50<sub>ii</sub>, the level of the i-th drug needed to achieve 50% neutralization of the j-th 75 viral strain). We also allow some fraction  $\omega$  of strains to be completely resistant. Then, from titer, or the 76 ratio of concentration to IC50 of each antibody against a certain strain, we define neutralization using a 77 logistic function, which defines the proportion (0-1 scale) of viruses that are neutralized. There are four 78 functional PD interaction scenarios. The first two are heuristic taking either the worst (minimum) the best 79 (maximum) titer or neutralization between two products. The other two are mechanistic combinations

80 described by independently combining titers (additivity) or neutralization (Bliss Hill). Then, depending on

81 the PKPD outcome measure of interest (for example titer, neutralization, coverage defined below) and

82 when that measure should be evaluated (throughout the study = AUC, at the low point = trough), we

83 identify the optimal ratio of the antibodies to be included in the initial dose.

We previously integrated pharmacokinetic (PK) and multi-strain pharmacodynamic (PD) models to determine longitudinally varying potency of VRC01, a broadly neutralizing antibody (bNAb), to simulate prevention trials and predict strain coverage<sup>18,19</sup>. Because of HIV genetic diversity, it is essential to consider the distribution of potencies against the diverse population of viral strains. We now extend this framework to model multiple bNAbs, where integrating the combination PD models with PK adds several layers of complexity (**Fig 1**).

90

91 **Pharmacokinetics (PK) for bNAb levels.** The first component of the PKPD framework is the PK, describing 92 concentrations of each antibody *i* over time, *t*:  $C_i(\boldsymbol{\theta}_i, t, d_i)$  where  $\boldsymbol{\theta}_i$  are the bNAb specific PK parameters 93 and  $d_i$  is the initial dose (PK model in **Fig 1**). Individual initial dosing for each bNAb is then constrained by 94 a total dose ( $D = \sum_i d_i$ ). For simplicity, we assume a population-level fixed total dose and independent 95 models of PK for multiple bNAbs (denoted  $C_i(t)$  from here on). The model could be extended to 96 implement individual-specific total dosing (e.g., bodyweight-adjusted) and joint, dependent models.

97

Pharmacodynamics (PD) for bNAb potency. Two pharmacodynamic (PD) quantities are often used to
 discuss neutralization given concentration: 50% inhibitory dose or dilution neutralization titer (ID50 Titer)
 and percent neutralization. Both quantities incorporate concentration and 50% inhibitory concentration
 (IC50) measurements across a panel of viruses (PD model in Fig 1).

102 Experimental neutralization titer (ID50),  $\tau_{ij}(t)$ , is a common measurement arising from titrated 103 neutralization experiments. In practice, experimental ID50 represents a dilution factor applied to sera 104 containing antibodies that reduces *in vitro* neutralization to 50%. Titer, and the similarly derived ID80, are 105 important immunological endpoints that are proven correlates of protection<sup>4,17</sup>. Experimental titer can be 106 theoretically predicted from the ratio of *i*-th drug concentration to *j*-th virus IC50 as

107  
108 
$$\tau_{ij}(t) = \frac{C_i(t)}{1C50_{ij}'}$$
 Eq 1

109

a relationship that has been empirically confirmed for single bNAbs<sup>19,20</sup>. As a potency measure, titer
 expresses the fold-relationship between concentration and viral IC50 as a measure of 'protection' against
 that virus.

Experimental *in vitro* neutralization for a single bNAb against a virus is also theoretically related to the titer (**Fig 1**). Neutralization, on a 0-100% scale, has the mechanistic interpretation of the fraction of blocked cellular infection events by the *j*-th virus, or "% neutralization". Titer and neutralization,  $\nu$ , can be related through the logistic Hill function (or median-effect equation) as follows

117 
$$v_{ij}(t) = \left\{1 + \tau_{ij}(t)^{-h_{ij}}\right\}^{-1}$$
. Eq 2

118 Neutralization requires an additional parameter, the `Hill coefficient'  $h_{ij}$ , that describes the steepness of

the neutralization curve. Through Eq 2, any generalized titer (e.g., ID80, ID99) can be predicted from the

120 ID50 titer and a given Hill slope, where the Hill slope can be estimated from IC50 and IC80 measurements

121 (see **Supplementary Information**). Using the CATNAP database<sup>21</sup> of IC50 and IC80 neutralization estimates

- 122 for HIV virus/antibody combinations, we estimated the distribution of Hill slopes and generally found
- values near 1 (See Methods and **Supplementary Figure 1**). Henceforth in our analysis, and consistent with previous measurements<sup>18</sup>, we set  $h_{ij} = 1$  and it is dropped from equations. Under this assumption, the

125 IC80 is theoretically predicted to be 4-fold higher than the IC50, and, subsequently, the ID80 is predicted

126 to be 4-fold lower than the ID50 for single bNAb and virus combinations (see Supplementary Information 127 for more details).

128

129 **bNAb interaction models.** For bNAb combinations, we considered 4 PD interaction models. The first, Bliss-130 Hill independence (BH), is the best-case multiplicative interaction where bNAbs cover missing breadth of 131 one another and co-neutralize strains, i.e., virions must escape independent binding events from each 132 antibody. BH is encouragingly observed from *in vitro* studies<sup>10,22</sup>. We also consider weaker cooperation 133 with the additivity interaction model, where antibody effects are combined via mass action<sup>10</sup>; i.e., the 134 total titer is sum of individual titers. Finally, maximum and minimum models assume that the more or less 135 potent antibody for each strain operates as a single product. The maximum interaction potentially 136 represents a scenario where only the most potent bNAb neutralizes a given virus; however, outcome 137 deviations between the maximum and the BH or additivity model also highlight where interactions 138 improve neutralization due to combined coverage. On the other hand, the minimum model is 139 mechanistically unrealistic but provides a boundary for the worst-case scenario where the combination 140 regimen is only as strong as its weakest link, specifically penalizing poor combined coverage of viruses.

141 The interaction models are mathematically summarized in **Table 1** and all derivations of 142 combinations titers are included in the **Supplementary Information**. We extend interactions to include 143 synergy in the bi-specific antibody case study, but do not consider antagonism among clinically viable 144 bNAb combinations here.

Table 1. Summary of equations for PD interaction models relating bNAb (*i*) to virus (*j*). Formula for Bliss Hill ID50 illustrated for 2-bNAb combinations only.

PD Outcome	Bliss Hill (BH)	Additivity	Maximum	Minimum
Titer (ID50) $ au_{ij}(t)$ , Eq 1	$\frac{2\tau_{1j}\tau_{2j}}{-(\tau_{1j}+\tau_{2j})+\sqrt{(\tau_{1j}+\tau_{2j})^2+4\tau_{1j}\tau_{2j}}}$	$\sum_i \tau_{ij}(t)$	$\max_i[\tau_{ij}(t)]$	$\min_i[\tau_{ij}(t)]$
Neutralization $ u_{ij}(t)$ , Eq 2	$1 - \prod_{i} [1 - v_{ij}(t)]$	$1 - \left[1 + \sum_{i} \tau_{ij}(t)\right]^{-1}$	$\max_i[v_{ij}(t)]$	$\min_i[v_{ij}(t)]$

147

Other options exist to quantify antibody potency, including instantaneous inhibitory potential (IIP<sup>23</sup>), the log-fold reduction in virus infectivity at a given concentration, which linearizes high neutralization on the log-scale (e.g., 99% neutralization -> IIP of 2, 99.9% -> 3) in the important range for ART efficacy<sup>23</sup>.

151  
152 
$$IIP_{ij}(t) = -\log_{10}[1 - v_{ij}(t)] = \log_{10}[1 + \tau_{ij}(t)].$$
Eq 3  
153

154 A generalized version of IIP when  $h_{ij} \neq 1$  is described in the **Supplementary Information**.

155 Alternatively, the potency of an antibody combination can be quantified by its "viral coverage": 156 what fraction of viral strains are above a specified threshold value. Fundamentally, the neutralization 157 measurement is dichotomized for a given bNAb/virus combination, i.e., the virus is neutralized or not 158 based on some measurement threshold. For example, for *n* strains and a neutralization threshold  $v^*$ , we 159 define the neutralization coverage fraction  $f(t, v^*) = \frac{1}{n} \sum_{j=1}^n \mathcal{I}(v_{ij}(t) > v^*)$  where  $\mathcal{I}$  is the indicator 160 function equal to 1 if the inequality holds and 0 otherwise.

161

162 **Mathematical model for optimizing antibody combination doses.** Finally, we summarize these 163 measurements of potency over time, which we collectively term PKPD outcomes. We consider PKPD 164 outcomes at trough (pre-specified final time) or throughout time (area under the curve, AUC) (Fig 1).

In practice, for a specified antibody combination, we obtain their PK parameters and the best estimate of their distribution of IC50s to a relevant panel of circulating viruses. We can then choose an interaction model and specify an outcome that we want to optimize. From this we uniquely determine the optimal ratio of the antibodies. Potential combinations of bNAbs—varying by their input PK and PD profiles—can then also be evaluated and compared via mathematical PKPD simulations at the optimal

170 dosing ratios, which may be combination-dependent, as illustrated in the *in silico* studies below.

171 Global sensitivity analysis. Across a range of theoretical 2-bNAb combination studies, we performed a 172 global sensitivity analysis varying all input PKPD model parameters (Fig 1) to assess correlation between 173 all PKPD outcomes and optimized dosing ratios (see **Methods**). Briefly, we varied one-compartment 174 exponential PK models for each antibody summarized by their half-life  $hl_i$ . One bNAb was simulated to 175 always have equivalent or better half-life than the other to avoid redundancy. We chose a log-normal 176 distribution for IC50s for each bNAb parameterized by its mean  $\mu_i$  and standard deviation  $\sigma_i$  on the log10 177 scale, also allowing for a fraction  $\omega_i$  that are completely resistant (infinite IC50). We also varied the ratio 178 of doses r and the total dose D. The ranges explored for each sensitivity analysis parameter are collected 179 in Table 2.

- 180
- 181 **Table 2.** Parameter settings for PKPD sensitivity analysis for combining 2 bNAbs.

Parameter	Sensitivity analysis values
Initial dose (mg)	{150, 300, 600, 1200, 2400}
Half-life (days)	{7, 28, 42, 84}
Total simulated viruses	500
% viral resistance	{67, 33, 0}
Mean log10 IC50 (μg/mL)	{-3, -2, -1}
SD log10 IC50 (µg/mL)	{0.25, 0.5, 1}

182

183 Publicly available tool for ratio optimization. Any individual simulation from the results can be generated 184 using the following R shiny app: https://bnabpkpd.fredhutch.org.

185 **PKPD outcomes cluster into categories.** Using global sensitivity analysis output, we calculated Spearman 186 correlations among all endpoints at trough (Fig 2A). By hierarchical clustering, we determined six main 187 categories of outcomes (Fig 2A): All models with the minimum interaction (i.e., worst-case bNAb 188 penalizing lack of combination viral coverage) and raw titer (ID50) endpoints for the non-minimum 189 interaction were quite distinct. The remaining outcomes were correlated but further categorized as 190 neutralization, log<sub>10</sub>-transformed titer, coverage metrics (% of viruses neutralized > 99%), and IIP. Results 191 were similar for AUC and trough, see Supplementary Fig 2, which indicates for a simple monotonic PK 192 curve, the final value is representative of the entire time-course.



194 Fig 2. Correlations among PKPD outcomes and between model parameters and outcomes. We 195 performed a global sensitivity analysis to simulate a two-drug combination therapy against a genetically 196 diverse pathogen where the drug 1 had equivalent or worse half-life than drug 2. We simulated 24 197 outcomes at trough (results for AUC are similar), including ID50, log10 ID50, neutralization, instantaneous 198 inhibitory potential (IIP), as well as the coverage fraction of pathogen strains having ID50>100 and IIP>2. 199 A) Many of these outcomes are strongly correlated (yellow in heatmap). Moreover, these 24 outcomes 200 cluster into approximately 6 distinct categories: see labels along dendrogram. Of the interaction models, 201 only the minimum interaction separated into its own category while the others clustered together within 202 a given outcome. B) Overall, we varied 10 model parameters (Table 2). By correlating (Spearman, green~1, 203 pink~-1) to the 6 categories from panel A against all model parameters, we found that the categories were 204 similarly sensitive to PK, while titer and minimum categories were less sensitive to resistance fractions. The 205 ratio does not strongly predict any outcomes when all other parameters are varied, highlighting that there 206 is no general solution to optimizing the ratio and it must be adjusted on a case-by-case basis.

193

207 Correlations among PKPD outcomes and antibody features. We next explored the associations between 208 a representative member of each outcome category and model parameters (Fig 2B). All categories were 209 sensitive to PK (half-life), and generally more to the half-life of the shorter-lived bNAb (hl2). Increased 210 resistance negatively correlated with the outcomes, particularly with neutralization, log10-transformed 211 titer, coverage metrics, and IIP. Additionally, a stronger negative correlation was found with the resistant 212 fraction for the bNAb with longer half-life – this pattern was weaker for mean IC50. Total dose correlated 213 positively with all outcomes but was generally less influential than other model parameters. The ratio of 214 antibodies did not strongly predict any outcome after accounting for variation in all other parameters, 215 highlighting that there was no generally optimal ratio; optimization is determined on a case-by-case basis 216 based on many antibody features.

217

218 Sensitivity of the optimal ratio for each outcome. Next, for each parameter set, we determined the 219 optimal ratio r for each outcome. Fig 3A shows an analogous clustering analysis to Fig 2 but with 220 correlations of the optimal ratio of each outcome across the inputs. Importantly, the same categories 221 emerged such that correlations among all outcomes agreed generally with correlations among optimal 222 ratios. In particular, the optimal ratio for minimum not only appears distinct from the other categories 223 but is often negatively correlated to the others. This suggests that optimizing for minimum interaction 224 (i.e., maintaining consistent combination coverage) may require a very different ratio. For the other 225 interactions, once an outcome is selected, the optimal ratios generally agree among maximum, additive, 226 and Bliss-Hill interaction models.

Fig 3B shows correlations among optimal ratios for each outcome and model parameters. Here directionality of correlation has additional meaning: positive and negative correlations imply less or more of the antibody with worse half-life, respectively. The sensitivity to PK and PD (resistance and mean IC50) followed the same pattern as in Fig 2A: all the outcomes showed some sensitivity to PK, titer and minimum interaction outcomes were sensitive to mean IC50, and the remaining were sensitive to resistance fractions. For ratio optimization, the PK sensitivity was specifically driven by the half-life of the shorterlived bNAb.

234 We next sought to understand what is gained by using the optimal ratio as opposed to a more 235 practical solution near the optimum. Therefore, we measured how many parameter combinations 236 admitted an outcome within 95% of the outcome value achieved by the optimal ratio (Fig 3C). That is, if 237 most simulations were within 95% of the optimum, it means the optimum is not substantially better. 238 Indeed, for the parameter ranges we considered, some outcomes were not particularly sensitive to the 239 choice of the optimal ratio such that other practical considerations could be promoted in a trial design. 240 However, some outcomes were much more strongly affected by optimization (with fewer than  $1/10^4$  runs 241 being in the 95% optimal scenario) including IIP. So, although there are cases of insensitive systems (e.g., 242 two poor products, two highly effective products), this reinforces that optimization should be case-243 specific.





244 245 Fig 3. Sensitivity of the optimal ratio to PKPD outcome choices and antibody features. From the global 246 sensitivity analysis, we calculated the optimal ratio for each parameter set and each outcome. (A) We 247 repeated the clustering analysis to determine how the optimal ratio clusters by outcome. In this setting 248 coverage and IIP cluster together leading to 5 (rather than 6) categories, but the others remain the same 249 from the prior analysis in **Fig 2**. B) Certain variables drive optimization for different outcomes. For example, 250 the mean IC50 are most influential on optimizing ratios using minimum neutralization and titer outcomes, 251 while the fraction resistant is most influential for the remaining outcomes. C) Across all simulations, we 252 quantified the sensitivity of the optimal ratio of each outcome by calculating the fraction of parameter 253 sets in which the outcome was within 95% of its optimal value. For the parameter ranges considered, some

of these outcomes were not enhanced greatly by perfect optimization, but outcomes clustered in the correlation showed similar sensitivity and some outcomes were particularly sensitive.

256

257 Dual parental antibodies outperformed bispecific product without synergy enhancement. Bi-specific 258 antibodies, synthesized combinations of two antibodies into one product, appear in vitro to exhibit 259 superior neutralization compared to their parental components<sup>13,14</sup>. However, these experiments are not 260 inclusive of in vivo pharmacokinetics. Bi-specific antibody clearance may be determined based on the 261 clearance kinetics of either parental component. If clearance characteristics are comparable to the slower 262 of the two parental antibodies, then the bi-specific combination is clearly advantageous. Because bi-263 specific PK is not well studied, we tested the non-trivial scenario in which a bi-specific inherits the worse 264 (faster) parental half-life. We investigated a realistic design administering 300 or 1200 mg of antibodies 265 and 3-month administration window. We assumed one parental antibody had a 3-month half-life 266 equivalent to the trough time but with worse PD than a superiorly potent bNAb. However, the more 267 potent bNAb was given a poorer half-life of 1 week (i.e., equivalent to 1/12 of trough window). We 268 evaluated the theoretical study efficacies using the following PKPD outcomes: a continuous outcome 269 (mean IIP) and a coverage outcome (% viruses IIP>2).

Compared to the combination therapy, the superior potency of the bi-specific antibody is not necessarily sufficient to account for a poor PK profile. Across doses and interaction models, we consistently found that the optimal combination therapy was more efficacious than the bi-specific for both AUC and trough (**Fig 4**). At trough, where half-life had higher influence, the parental with better halflife but worse PD alone outperforms the bi-specific particularly at lower doses.

Given this finding, we tested how much additional synergy (as a factor multiplying the bi-specific potency through reduced IC50, see **Methods**) could rescue the bi-specific performance and make it comparable to the parental combination. Synergy has been observed for bi-specifics because binding of one antibody arm can facilitate the second to bind<sup>24</sup>. Using synergy models, the bi-specific outperformed the optimized combined administration when the synergy factor exceeded 10-fold under common interaction models (**Fig 4**).



281 282 Fig 4. Optimizing 2 bNAb combination therapy in comparison to bi-specific therapy with the same 283 **bNAbs.** Combination antibody results for AUC (top) and trough (bottom) suggest that trough is slightly 284 more sensitive to ratio (see curvature of outcome surface and change from optimal ratio denoted by open 285 dot). In general, a single bi-specific bNAb will perform worse than combination therapy if it has the best 286 neutralization potential of both parental lineages under a common interaction model but inherits the 287 faster clearance kinetics. However, if synergetic binding occurs, enhancing the bi-specific potency by 10-288 fold (see **Methods**), it is similar or outperforms the optimal combination for all outcomes and doses. "All 289 bNAb1" and "All bNAb2" on the x-axis correspond to 100% dosing of the second bNAb product.

**Incorporating empirical protection correlates in clinical design.** To perform a realistic optimization of a clinical trial, we consider deviations from *in vitro* potency that may be relevant for *in vivo* protection. For example, non-human primate HIV challenge studies suggest that a bNAb titer of approximately 100 achieved 50% protection: i.e., serum antibody concentrations need to be 100-fold higher than *in vitro* IC50 to elicit 50% protection *in vivo*<sup>17</sup>. We define the fold-increase as a "potency reduction factor"<sup>18</sup>,  $\rho$ , and

henceforth translate *in vitro* potency to *in vivo* protection by scaling the titer input. We have *in vivo* neutralization and IIP then,

297	$\nu^{invivo}(t) = \left\{1 + \left[\tau_{ij}^{invitro}(t)/\rho\right]^{-1}\right\}^{-1},$	Eq 4
298	$IIP_{ij}^{invivo}(t) = \log_{10} \left[ 1 + \tau_{ij}^{invitro}(t) / \rho \right].$	Eq 5

299

such that no change from *in vitro* measured titer occurs when  $\rho = 1$  and a potency reduction of 100-fold means  $\rho = 100$ . Mechanistically, this formulation suggests that the overestimated protection *in vivo* is due to either (or both) underestimation of the potency due to some biological factors (e.g. coagulation or anti-antibody elements) or overestimation of bNAb concentration at the site of exposure.

The reduction factor can be derived from assessing actual protection at the given experimental titers, either through NHP challenge or using protection efficacy (PE) estimated from clinical study. Alternatively, if multiple protection estimates for varying titers, the titer vs. protection dose-response relationships can also be structurally varied; for example, we employed a 5-parameter logistic model on the NHP protection data for the following case study (see **Methods**).

309 For combination bNAbs, the experimental titer will represent neutralization in sera with a 310 combined concentration of antibody. Whether a potency reduction factor is applied to the combination 311 titer or to the individual titers prior to the interaction is specifically consequential for the Bliss-Hill 312 interaction model, but not the other interaction models. Briefly, applying the factor to the Bliss-Hill 313 combination titer model may be overly conservative, underestimating the protection because 314 experimental titer does not uniquely predict Bliss-Hill neutralization (Supplementary Figure 3; see 315 Supplementary Information for further discussion). We suggest applying the potency factor or protection 316 model to each bNAb individually, calculating their individual protection estimate, then applying the Bliss-317 Hill interaction model (i.e., at the event-level) as described in the following case study.

318

319 Using empirical protection correlates in a 3-bNAb optimization. We gathered several independent data 320 sets to model a 12-week trial with a 600 mg subcutaneous dose of 3 state-of-the-art broadly neutralizing 321 antibodies (3BNC117-T, 10-1074-T, VRC07-523-LS; -T denotes theoretical variant with extended half-life). 322 For this example, we used an empirical protection estimates based on titer from the Pegu et al. NHP meta-323 analysis<sup>17</sup> with the primary PKPD outcome of viral coverage at 50% and 95% protection thresholds. For 324 more details on the input PK and PD for these analytes, see **Methods** and **Supplementary Figure 4.** In this 325 illustrative example, we do not consider clade-specific profiles nor account for interference potentially 326 due to 3BNC117 and VRC07-523-LS targeting the same epitope (CD4-bs). Next, we tested all double and 327 triple combinations varying the dosing ratios. In a clinical setting, it is unlikely that complicated dosing 328 ratios would be of practical consideration (e.g., 98:13:3). Thus, for the 3-bNAb combination, we 329 considered simple ratio designs: an even dose split (denoted 1:1:1) or any 50%:25%:25% combination 330 (denoted 2:1:1 or similar). We compared this to the theoretical optimum to ensure they were reasonably 331 close to the optimal design.



332 333 Fig 5. Additional enhancement after optimization of 3-drug therapy. Using 3 well known anti-HIV broadly 334 neutralizing antibodies, we performed an analysis comparing the percent of viruses at more than 50% and 335 95% neutralization level for the bNAbs individually, in 1:1 combination, and in triplicate as 1:1:1, 1:1:2, 336 1:2:1, 2:1:1, and the optimal combination (see Table S2). Enhancement over the best single bNAb (VRC07-337 523-LS) is generated through combinations when evaluating the percent of the viruses neutralized at a 338 95% level. However, triple drug therapy does not meaningfully enhance over optimized 2-drug therapy 339 levels, even when completely optimized. Indeed, a 1:1:1 3 drug therapy is outperformed by the optimized 340 2-drug therapy, highlighting the need to carefully perform case-studies for any optimization scenario.

341 Overall, all triple drug combinations predicted a protection level above 95% for roughly 25% of viruses at 342 trough. Likewise, protection levels were above 50% for roughly 80% of viruses over the study (AUC). It 343 was clear that VRC07-523LS was the best single antibody, and the optimal dosing ratio generally contained 344 >60% of VRC07-523-LS (see Table S2). Subsequently, the triple combination with 1:1:2 level of VRC07-345 523LS was not much worse than optimal. Moreover, the optimal 2-drug combination without 3BNC117-T 346 was nearly as effective as the optimal 3 drug therapy (which dosed at <10% of 3BNC117-T) potentially due 347 to general lower potency of 3BNC117 or the overlap in epitope targeting with VRC07-523-LS resulting in 348 redundant viral coverage in the database. Still, given our necessarily incomplete data on circulating 349 strains, we would suggest using this 3-drug therapy at a 1:1:2 design to balance simplicity and protection

350 for this example.

#### Discussion 351

352 Combination administration of broadly neutralizing antibodies is likely to form a key component of future 353 studies of HIV prevention<sup>1,4,14,25</sup>. While antibody neutralization is essential, accurate balancing of antibody 354 dosing requires modeling both neutralization and concentration levels over time. Our approach here 355 addresses this critical unmet need.

356 Our analysis highlights that several types of data for each antibody in a combination modality must all be 357 considered to optimize dosing rationally. These include 1) the input potency data relating each bNAb to 358 existing in vitro assays that test drug potency (i.e., IC50); 2) a translation to an in vivo protection metric 359 using a correlate derived from NHP meta-analysis; and 3) an understanding of drug interactions. The 360 second step is crucial because in vitro IC50 measurements could underestimate *in vivo* efficacy<sup>18,26</sup>. While 361 we illustrate use of a NHP correlate, human correlates may soon be derived from the AMP trials. The best 362 correlate will likely need to be translational using readily available in vitro neutralization data for 363 predictions<sup>14,22</sup>, which may be calculated using pseudoviruses (e.g., CATNAP database<sup>21</sup>) or breakthrough 364 viruses in human infections<sup>27</sup>.

- 365 Here, we depict how to implement a titer protection correlate into clinical design for combinations. As 366 illustrated in our practical case study design using the NHP challenge correlate, we derive a dose-response 367 relationship for titer and protection from the NHP challenge studies, and then assess combinations using 368 this empirical protection as the PKPD outcome via viral coverage. We also highlight that the protection 369 estimates derived from single bNAb studies need to be carefully translated into combination bNAb target 370 outcomes. Specifically for the Bliss-Hill interaction, a combination sera titer may correspond to different 371 protection estimates depending on the underlying individual concentrations of each bNAb. We suggest 372 determining antibody-level protection first then applying the BH interaction. This approach is also 373 amenable if different potency reduction factors or dose-response protection relationships are bNAb-374 specific depending on target site.
- 375 Because there remains uncertainty regarding the optimal PKPD protection endpoints for bNAb 376 combinations, our sensitivity analysis illustrates several main categories with similar properties. 377 Moreover, we show certain features of antibodies (long half-lives, broad coverage, etc.) are particularly 378 predictive of success, raising the possibility of using these results to inform endpoint selection based on 379 coarse knowledge of circulating strains. While PK heterogeneity will affect endpoints and should be 380 considered for optimizing trial design, the endpoints we tested exhibited much more sensitivity to the PD 381 profile of the product. The optimal ratio of a two-drug therapy was shown to be strongly sensitivity to 382 specifics of the combined antibody features. Thus, in combination with additional demographic 383 considerations and population risk, we advocate for specific optimization for any trial rather than relying 384 on general rules. Additionally, certain endpoints are more sensitive to optimal dosing than others, which 385 can be considered in endpoint selection, or alternatively, if an endpoint is preferred which is not 386 particularly sensitive, practical considerations about dosing could be prioritized over precise dose 387 optimization as illustrated by our 3-bNAb combination example.
- 388 In our sensitivity analysis, we also find that PKPD outcome levels and optimal ratio are well correlated 389 between the maximum, additivity, and BH interaction. This suggests that the design of the trial is not 390 particularly sensitive to selecting the correct interaction model among these choices; however, the correct 391 choice may still improve the accuracy of the predicted PKPD outcome. On the other hand, the minimum 392 interaction formed a unique cluster of simulated endpoints and optimized compared to others. While the 393 minimum interaction may be unrealistic, it explicitly penalizes designs that lack effective combination 394 coverage. In practice, a trial optimization may evaluate both a minimum and Bliss-Hill interaction 395 endpoints, allowing the minimum interaction to represent a worst-case scenario where there is no 396 protection against viruses without sensitivity to at least two bNAbs.
- Although most of our analysis concerns prevention studies, this framework is applicable to curative studies attempting to use bnAbs to prevent viral rebound after stopping ART<sup>28,29</sup>. The challenge in this setting is within-host diversity in the reservoir. Blocking a single founder during a transmission event appears easier than blocking repeated reactivations of diverse viral populations. Several studies have illustrated bnAbs can delay viral rebound<sup>28–30</sup>. However, levels required to prevent rebound remain hard

402 to predict. In a cohort of 18 individuals receiving VRC01 infusion and ART cessation rebound occurred 403 when plasma VRC01 levels were well above *in vitro* IC50s<sup>29</sup>.

404 Our analysis shows potential limitations around bi-specifics once PK is considered. Specifically, if the 405 synthetized product clears faster, performance can be worse than an optimized combination therapy of 406 the two parent products. The prevention benefits from bi-specific products thus rely on beneficial co-407 binding represented through some synergy, but these benefits may trade off with poorer half-life. 408 Without synergy, bi-specifics are effectively a 2-fold concentration bonus, but neutralization is relatively 409 insensitive on this scale, requiring input changes on the log-scale to either IC50s or concentrations. Of 410 note, a powerful synergistic effect may allow these products to be potent at unmeasurable concentrations 411 (i.e., below a typical limit of detection), which may not be tenable for study and practical use in a clinical 412 setting. On the other hand, bi-specifics may be clinically preferable as they are a single product, and if the 413 PK is at least half the dosing interval (or trough time), then our analysis suggests they theoretically perform

414 comparably or better than combinations without consideration of synergy.

The three-drug optimization exercise illustrates that one potent antibody can determine the ability of combinations. Indeed, in this specific example, a two-drug therapy would have been nearly as good. However, in considering that viral panels are necessarily incomplete, we would err on the side of inclusivity to both widen breadth and account for uncertainty about escape mechanisms. In this example,

- 419 adding the third and optimizing the triple-drug ratio is always beneficial to the two-drug combination,
- 420 albeit minorly.

421 Going forward, our recommendation for designing therapeutic combinations for prevention or treatment

422 of diverse pathogens is several fold: 1) choose outcomes based on expert opinions and given

423 disagreements, assess whether these qualitative decisions are actually quantitatively in agreement; 2)

424 consider multiple, distinct outcomes to evaluate a range of potential results; 3) optimize drug ratios for

- 425 the specifics of component features; and 4) include subdominant levels of weaker antibodies to
- 426 potentially cover holes in coverage not observable from incomplete preliminary data.

## 427 Methods

428 **Code and data.** All analysis were performed in R and Python. Simulations, data processing, and 429 visualizations performed using R used the *tidyverse* package suite<sup>31</sup>. Sensitivity and cluster analysis of 430 simulation results with subsequent visualizations were performed using the seaborn library in Python. All

431 code will be available on GitHub.

432 Estimation of Hill slope using CATNAP data. The Hill slope in the 2-parameter logistic Hill function (Eq 2) 433 can be estimated from the IC50 and IC80 measurements (formula derived the Supplementary 434 **Information**). We estimated the distribution of the neutralization Hill slope by performing this calculation 435 across virus/antibody combinations available in the LANL CATNAP database<sup>21</sup>. To accommodate assay 436 quantification limits that potentially vary across experimental study, we limited the analysis datasets to 437 IC50 and IC80 values between 0.01 and 20 ug/mL, comprising 20,236 total combinations. Additionally, we 438 grouped calculations within quartiles of input IC50 to assess whether Hill slopes vary by underlying viral 439 sensitivity or measurement error that varies with the scale of IC50.

**Global sensitivity analysis.** We performed ~10,000 simulations over all combinations of parameters in Table 2 and calculated all PKPD outcomes. We chose a one-compartment exponential PK model with trough time 84 days for each bNAb:  $C_i(t) = C_i(0) \exp(-k_i t)$ , and summarized the PK model with its halflife  $hl_i = \ln 2/k_i$ . The PK model used a one compartment model with fixed volume of distribution (3 L)<sup>32,33</sup>.

- 444 One bNAb was simulated to always have equivalent or better half-life than the other to avoid redundancy.
- 445 We chose a log-normal distribution for IC50s for each bNAb parameterized by its mean  $\mu_i$  and standard

446 deviation  $\sigma_i$  on the log<sub>10</sub> scale, also allowing for a fraction  $\omega_i$  that are completely resistant (infinite IC50).

447 We sampled 500 viruses per simulation. We then varied these parameters, along with the ratio of doses

r and the total dose D. Then, we determined the optimal ratio as the ratio that maximized each PKPD

449 outcome for all other parameter values across interaction models. To calculation IIP under Bliss-Hill,

450 neutralization calculated for each bNAb and used as input, not titer (see **Supplementary Information**).

Using the seaborn package in Python, we performed hierarchical clustering of Spearman correlationsamong outcomes and between parameters and outcomes.

453

454 **Comparison of bi-specific to parental antibodies.** For the first parental bNAb, we chose a potent 455 neutralizer (mean IC50 of  $10^{-3}$  with 0% viral resistance) but with poor PK: elimination half-life equivalent 456 to 1/12 of the administration period (i.e., 7-day half-life for an 84-day trough). For the second bNAb, we 457 chose a more modest neutralizing profile (mean IC50 of  $10^{-2}$  with higher variance and 33% viral 458 resistance) but with excellent PK: elimination half-life equivalent to one administration period.

To model the bi-specific, we assumed the single molecule formulation means two parental products are given at the identical dose. We also assumed the clearance PK was determined by the faster of the two parental products. We additionally allowed for synergy, such that each antibody's potency is improved by a factor  $\alpha$ . This factor was assumed to be the same for all viral strains. Thus, following **Eq 3** and **Table 2**, the bi-specific IIP against a single virus  $V_i$  can be calculated for max, min, and additivity models,

464 respectively

465	$IIP_{j} = \log_{10} \left[ 1 + \alpha \min_{i} \tau_{ij} \right],$	Eq 6
466	$IIP_{j} = \log_{10}[1 + \alpha \max_{i} \tau_{ij}],$	Eq 7
467	$IIP_j = \log_{10}[1 + \alpha \sum_i \tau_{ij}].$	Eq 8

468

For Bliss-Hill interaction, the derivation from individual titers to a combination IIP is shown in the **Supplementary Information (Eqs S27 & S29)** and then the bi-specific synergy was implemented as follows:

Eq 9

472 
$$IIP_{j} = \sum_{i} \log_{10}[1 + \alpha \tau_{ij}].$$

For comparing the combination and bi-specific therapies, we examined IIP and % viruses having IIP>2 (a surrogate of protection in nonhuman primate studies<sup>17</sup>) for AUC and trough. Calculations were based on 500 simulations as implemented for the global sensitivity analysis.

**Realistic clinical trial simulation.** The full trial design contained a 12-week observation window and 600 mg total subcutaneous (SC) dosing with PK parameters established from clinical study (Table S1 and **Supplementary Fig 4A**). To boost performance of 3BNC117 and 10-1074, we artificially enhanced their half-lives by 3-fold to mimic an -LS variant (3BNC117-T and 10-1074-T). The distribution of *in vitro* neutralization against circulating strains was modeled using *in vitro* derived IC50s from 507 available common strains in the LANL CATNAP database<sup>21</sup> (**Supplementary Fig 4B**).

482 We tested several models to map in vivo protection from in vitro neuralization. Pegu et al. 483 developed a logistic regression model to predict protection probability from *in vitro* neutralization titer<sup>17</sup>. 484 We use the output of their model at 50%, 75%, and 95% protection to test our model (Supplementary Fig 485 **4C**). Specifically, we employed the following approach: for a given bNAb (i) at a given concentration, we 486 estimated *in vivo* protection (p) using neutralization titer ( $\tau_{ii}$ ) against a virus (j). Using Eq 3 and estimating 487 a single parameter, the potency reduction, found  $\rho=1/91$  and led to reasonable fits. However, a better fit 488 was achieved using a 5-parameter logistic (5PL) model, a generalized dose-response type function with 5 489 parameters {A, B, C, D, E} and the form

490

491 
$$y(x) = D + (A - D)\{1 + \exp[B(\log(x) - \log(C))]\}^{-E}$$
, Eq 10

here mapping *in vitro* titer  $x = \tau_{ij}$  and to *in vivo* protection  $y = p_{ij}$ . We fixed D = 0 and A = 1 so that protection ranges from 0-1. The remaining 3 parameters were estimated as B = -1.84, C = 257, and E = 0.338. The best fit of the potency reduction model and the 5PL model are compared in

## 496 Supplementary Fig 4C.

We then illustrate predictions of the 5PL model for each bNAb via % viral coverage at *in vitro* neutralization >50% compared to *in vivo* protection >50 and >95% in **Supplementary Fig 4D**. Using this model of protection, we then calculated combined protection across the administered bNAbs (*b* is the number of antibodies considered) assuming independence similar to Bliss-Hill: 501

502 
$$p_j = 1 - \prod_i^b (1 - p_{ij})$$
 Eq 11  
503

504 We then defined our protection PKPD outcome as viral coverage fraction such that we can determine 505 what % of all viruses have protection above a certain threshold value *X*:

507 
$$f(t,X) = \frac{1}{n} \sum_{j=1}^{n} \mathcal{I}(p_j(t) > X)$$
 Eq 12

508

506

492

509 where  $\mathcal{I}$  is the indicator function equal to 1 if the inequality holds and 0 otherwise.

510 We assessed PKPD at the trough time (12-weeks, T) and as an average over the administration 511 period (AUC/T over time through T). 512

# 513 **References**

- 5141Stephenson KE, Wagh K, Korber B, Barouch DH. Vaccines and Broadly Neutralizing Antibodies for515HIV-1 Prevention. Annu Rev Immunol 2020;38:673–703. https://doi.org/10.1146/annurev-516immunol-080219-023629.
- 5172Gao F, Bonsignori M, Liao HX, Kumar A, Xia SM, Lu X, et al. Cooperation of B cell lineages in518induction of HIV-1-broadly neutralizing antibodies. Cell 2014;158:481–91.519https://doi.org/10.1016/j.cell.2014.06.022.
- Wang S, Mata-Fink J, Kriegsman B, Hanson M, Irvine DJ, Eisen HN, *et al.* Manipulating the Selection
   Forces during Affinity Maturation to Generate Cross-Reactive HIV Antibodies. *Cell* 2015;160:785–
   https://doi.org/10.1016/j.cell.2015.01.027.
- 5234Gilbert PB, Juraska M, DeCamp AC, Karuna S, Edupuganti S, Mgodi N, *et al.* Basis and Statistical524Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials.525Stat Commun Infect Dis 2017;9:. https://doi.org/10.1515/scid-2016-0001.
- 5265Corey L, Gilbert PB, Juraska M, Montefiori DC, Morris L, Karuna ST, et al. Two Randomized Trials of527Neutralizing Antibodies to Prevent HIV-1 Acquisition. N Engl J Med 2021;384:1003–14.528https://doi.org/10.1056/NEJMoa2031738.
- 5296Roychoudhury P, De Silva Feelixge H, Reeves D, Mayer BT, Stone D, Schiffer JT, *et al.* Viral diversity530is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir. *BMC Biol*5312018;16:75. https://doi.org/10.1186/s12915-018-0544-1.
- 532 7 Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, *et al.* Antiretroviral Prophylaxis
  533 for HIV Prevention in Heterosexual Men and Women. *N Engl J Med* 2012;**367**:399–410.
  534 https://doi.org/10.1056/NEJMoa1108524.
- 5358Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure Prophylaxis536for HIV Infection among African Women. N Engl J Med 2012;367:411–22.

### 537 https://doi.org/10.1056/NEJMoa1202614.

- 5389Molina J-M, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-Demand Preexposure539Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med 2015;373:2237–46.540https://doi.org/10.1056/NEJMoa1506273.
- 54110Kong R, Louder MK, Wagh K, Bailer RT, deCamp A, Greene K, *et al.* Improving Neutralization542Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major543Neutralization Epitopes. J Virol 2015;89:2659–71. https://doi.org/10.1128/JVI.03136-14.
- 54411Wagh K, Bhattacharya T, Williamson C, Robles A, Bayne M, Garrity J, *et al.* Optimal Combinations545of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. *PLoS*546*Pathog* 2016;**12**:e1005520-27. https://doi.org/10.1371/journal.ppat.1005520.
- 54712Schiffer JT, Swan DA, Magaret A, Corey L, Wald A, Ossig J, et al. Mathematical modeling of herpes548simplex virus-2 suppression with pritelivir predicts trial outcomes. Sci Transl Med 2016;8:324ra15-549324ra15. https://doi.org/10.1126/scitranslmed.aad6654.
- 55013Bournazos S, Gazumyan A, Seaman MS, Nussenzweig MC, Ravetch J V. Bispecific Anti-HIV-1551Antibodies with Enhanced Breadth and Potency. Cell 2016;165:1609–20.552https://doi.org/10.1016/j.cell.2016.04.050.
- Wagh K, Seaman MS, Zingg M, Fitzsimons T, Barouch DH, Burton DR, *et al.* Potential of conventional
   & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections.
   *PLoS Pathog* 2018;**14**:e1006860--24.
- 556 15 Gaudinski MR, Houser K V., Doria-Rose NA, Chen GL, Rothwell RSS, Berkowitz N, et al. Safety and 557 pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy 558 adults: phase 1 dose-escalation clinical trial. Lancet HIV 2019;6:e667-79. а 559 https://doi.org/10.1016/S2352-3018(19)30181-X.
- 56016Scheid JF, Horwitz JA, Bar-On Y, Kreider EF, Lu C-L, Lorenzi JCC, et al. HIV-1 antibody 3BNC117561suppresses viral rebound in humans during treatment interruption. Nature 2016;535:556–60.562https://doi.org/10.1038/nature18929.
- 56317Pegu A, Borate B, Huang Y, Pauthner MG, Hessell AJ, Julg B, et al. A Meta-analysis of Passive564Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection565against SHIV Challenge. Cell Host Microbe 2019;26:336-346.e3.566https://doi.org/10.1016/j.chom.2019.08.014.
- 56718Reeves DB, Huang Y, Duke ER, Mayer BT, Fabian Cardozo-Ojeda E, Boshier FA, et al. Mathematical568modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP)569trials. PLoS Comput Biol 2020; 16:1–27. https://doi.org/10.1371/journal.pcbi.1007626.
- 57019Huang Y, Naidoo L, Zhang L, Carpp LN, Rudnicki E, Randhawa A, et al. Pharmacokinetics and<br/>predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody572Mediated Prevention (AMP) trials. EBioMedicine 2021;64:103203.573https://doi.org/10.1016/j.ebiom.2020.103203.
- 57420Huang Y, Zhang L, Eaton A, Mkhize NN, Carpp N, Rudnicki E, et al. Prediction of serum HIV-1575neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial576participants Mediated Prevention (AMP) trial participants ABSTRACT. Hum Vaccin Immunother5772021;00:1–10. https://doi.org/10.1080/21645515.2021.1908030.
- 57821Yoon H, Macke J, West Jr AP, Foley B, Bjorkman PJ, Korber B, et al. CATNAP: a tool to compile,579analyze and tally neutralizing antibody panels. Nucleic Acids Res 2015;43:W213–9.580https://doi.org/10.1093/nar/gkv404.
- 58122Wagh K, Bhattacharya T, Williamson C, Robles A, Bayne M, Garrity J, et al. Optimal Combinations582of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. PLoS583Pathog 2016; 12:1–27. https://doi.org/10.1371/journal.ppat.1005520.
- 584 23 Laskey SB, Siliciano RF. A mechanistic theory to explain the efficacy of antiretroviral therapy. *Nat*

585 *Rev Microbiol* 2014;**12**:772–80. https://doi.org/10.1038/nrmicro3351.

- 58624Einav T, Bloom JD. When two are better than one: Modeling the mechanisms of antibody mixtures.587PLoS Comput Biol 2020;16:1–17. https://doi.org/10.1371/journal.pcbi.1007830.
- Hessell AJ, Jaworski JP, Epson E, Matsuda K, Pandey S, Kahl C, *et al.* Early short-term treatment
   with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques. *Nat Med* 2016;**22**:362–8. https://doi.org/10.1038/nm.4063.
- Schiffer JT, Swan DA, Magaret A, Corey L, Wald A, Ossig J, *et al.* Mathematical modeling of herpes
   simplex virus-2 suppression with pritelivir predicts trial outcomes. *Sci Transl Med* 2016;8:324ra15 324ra15. https://doi.org/10.1126/scitranslmed.aad6654.
- Lorenzi JCC, Mendoza P, Cohen YZ, Nogueira L, Lavine C, Sapiente J, *et al.* Neutralizing Activity of
   Broadly Neutralizing anti-HIV-1 Antibodies against Primary African Isolates. *J Virol* 2020.
   https://doi.org/10.1128/jvi.01909-20.
- 59728Mendoza P, Gruell H, Nogueira L, Pai JA, Butler AL, Millard K, et al. Combination therapy with anti-598HIV-1 antibodies maintains viral suppression. Nature 2018:1–21. https://doi.org/10.1038/s41586-599018-0531-2.
- Cale EM, Bai H, Bose M, Messina MA, Colby DJ, Sanders-Buell E, *et al.* Neutralizing antibody VRC01
  failed to select for HIV-1 mutations upon viral rebound. *J Clin Invest* 2020;**130**:3299–304.
  https://doi.org/10.1172/JCI134395.
- 60330Crowell TA, Colby DJ, Pinyakorn S, Sacdalan C, Pagliuzza A, Intasan J, et al. Safety and efficacy of604VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2,605randomised, double-blind, placebo-controlled trial. Lancet HIV 2019;3018:1–10.606https://doi.org/10.1016/S2352-3018(19)30053-0.
- 60731Wickham H, Averick M, Bryan J, Chang W, McGowan L, François R, et al. Welcome to the Tidyverse.608J Open Source Softw 2019;4:1686. https://doi.org/10.21105/joss.01686.
- 60932Davda JP, Dodds MG, Gibbs MA, Wisdom W, Gibbs JP. A model-based meta-analysis of monoclonal610antibody pharmacokinetics to guide optimal first-in-human study design. MAbs 2014;6:1094–102.611https://doi.org/10.4161/mabs.29095.
- 61233Huang Y, Zhang L, Ledgerwood J, Grunenberg N, Bailer R, Isaacs A, et al. Population613pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy614adults. MAbs 2017;9:792–800. https://doi.org/10.1080/19420862.2017.1311435.
- 615